Has Rinu Abraham, MD received payments from drug or device companies?

Yes. Drug and device makers reported $93,712 in general payments to Rinu Abraham, MD across 42 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Rinu Abraham, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Rinu Abraham, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Rinu Abraham, MD

Neurology · Phoenix, AZNPI 1518353234

Payments from drug & device makers

What this record shows

This record is dominated by grants: $87,780 of the $93,712 with a category attached, or 93.7%. Biogen accounts for 93.9% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $89,362 and has fallen 97.0% since, to $2,647 in 2025. Among neurology clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$93,712in general payments, 2019–2025

Across 42 payments — averaging $2231.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Biogen$88K
TG Therapeutics, Inc.$3K
AstraZeneca$677
Bristol Myers Squibb$638
Sanofi$368
EMD Serono, Inc.$366
plus $649 from 8 others

$116,013in research payments, 2019–2025

Across 17 payments — averaging $6824.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

F. Hoffmann-la Roche AG$58K
Bristol Myers Squibb$23K
Genentech, Inc.$18K
Novartis$16K
E.r. Squibb & Sons, L.L.C.$1K
Biogen$25

What the payments were for

Consulting fees$3,0003%
Speaking & faculty fees$6001%
Grants$87,78094%
Food & beverage$2,2412%
Education$910%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Biogen	6	$87,976
TG Therapeutics, Inc.	6	$3,037
AstraZeneca	6	$677
Bristol Myers Squibb	2	$638
Sanofi	4	$368
EMD Serono, Inc.	7	$366
Novartis	2	$234
Alnylam Pharmaceuticals Inc.	1	$121
Greenwich Biosciences, Inc.	2	$102
Sanofi-aventis U.S. LLC	1	$91
Lundbeck LLC	2	$46
Portola Pharmaceuticals, LLC	1	$23
Neurocrine Biosciences, Inc.	1	$19
E.r. Squibb & Sons, L.L.C.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

BRIUMVI$2,927
ZEPOSIA$600
SOLIRIS$366
AUBAGIO$352
ULTOMIRIS$175
Mavenclad$125
ONPATTRO$121
MAYZENT$112

How this compares

$93,712 in reported general payments places this provider in the 90th percentile of 388 neurology providers in Arizona.

See all neurology providers in Arizona →

Medicare billing

Part B allowed, 2024

$134,501

Medicare patients

116

Services billed

3,510

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov50	15	$152,951
CopaxoneGlatiramer Acetate	12	$65,995
Glatiramer Acetate	17	$47,625
Dimethyl Fumarate	18	$18,656
Dalfampridine ErDalfampridine	30	$8,786
Teriflunomide	17	$8,122
Modafinil	26	$1,314
Baclofen	47	$840
Duloxetine Hcl	39	$798
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine	16	$713
Gabapentin	34	$461
RizatriptanRizatriptan Benzoate	14	$391
Pregabalin	19	$227
Tizanidine Hcl	13	$224
Quetiapine Fumarate	11	$126

Paid to pharmacies, not to this prescriber.

Other neurology in Phoenix

Barry HendinPhoenix$2.3M
Maria OspinaPhoenix$2.1M
Suraj MuleyPhoenix$1.7M
Eric ErossPhoenix$778K
Steve ChungPhoenix$685K
Marwan SabbaghPhoenix$603K
Kerry KnievelPhoenix$509K
Lori TravisPhoenix$406K
Jeffrey GittPhoenix$275K
Todd SchwedtPhoenix$273K

See the full list for Arizona →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →